2型糖尿病患者血清血管性血友病因子、血小板活化因子水平与糖尿病肾病的关系

摘要/Abstract

摘要： 目的探讨2型糖尿病患者尿微量白蛋白(UALB)、血管性血友病因子(vWF)、血小板活化因子(PAF)变化及临床意义。方法研究对象分5组:糖尿病肾病患者(A组),2型糖尿病无肾病并发症患者(B组)、糖耐量受损者(C组)、糖耐量正常的2型糖尿病患者一级亲属(D组)、无2型糖尿病家族史糖耐量正常受试者(E组),每组30例,分别检测UALB、vWF、PAF水平,并进行统计分析。结果 A组UALB、PAF含量明显高于其他4组(P<0.01),其他4组间UALB、PAF差异无显著性(P>0.05);A组vWF含量与B、C、D组比较差异有显著性(P<0.05)。结论 2型糖尿病微血管并发症患者存在肾功能损害和血小板活化,两者变化同步,提示其血管损伤与PAF含量升高有关。

Abstract: Objective To observe the changes in urine albumin (UALB), von Willebrand factor (vWF) and platelet-activating factor (PAF) in different courses of type 2 diabetes. Methods Levels of UALB, vWF and PAF were determined in 30 type 2 diabetic nephropathy patients(group A), type 2 diabetic patients without DNP(group B, n=30), patients with impaired glucose tolerance (group C, n=30), the first-degree relatives of type 2 diabetic patients with normal glucose tolerance(group D, n=30) and 30 normal glucose tolerance subjects without family history of type 2 diabetes(group E). Results UALB and PAF contents were significantly higher in group A than in the other groups (P<0.01), while between the latter 4 groups, the contents showed no significant differences (P>0.05). Serum vWF level was significantly higher in group A than those in the other groups (P<0.05). Conclusion Renal dysfunction and platelet activation are present in type 2 diabetes with microvascular complications, and the synchronized changes between renal dysfunction and platelet activation indicate the involvement of elevated PAF in vascular injury.

中图分类号:

R587.1

方咏红, 张继平, 周少雄, 郑菊芬, 余永卫, 晏世刚, 范文奎, 陈月崧. 2型糖尿病患者血清血管性血友病因子、血小板活化因子水平与糖尿病肾病的关系[J]. 南方医科大学学报, 2005, 25(06): 729-731.

FANG Yong-hong, ZHANG Ji-Ping, ZHOU Shao-xiong, ZHENG Ju-fen, YU Yong-wei, YAN Shi-gang, FAN Wen-kui, CHENG Yue-song. Relationship between serum vWF and PAF in type 2 diabetic patients and diabetic nephropathy[J]. Journal of Southern Medical University, 2005, 25(06): 729-731.

参考文献

[1] Karamanos B, Porta M, Songini M, et al. Different risk factors of microangiopathy in patients with type 1 dabetes mellitus of short versus long duration. The eurodabiddm complication study [J].Diabetologia, 2000, 43(3):348-55.
[2] Greaves M, Malia RG, Goodfellow K, et al. Fibrinogen and von Willebrand factor in IDDM:relationships to lipid vascular risk factors, blood pressure, control and urinary albumin excretion rate:The EURODIAB IDDM Complications Study [J]. Diabetologia,1997,40(6):698-705.
[3] Ingerslev J. Research methodologies in measurement of platelet function, endothelial proteins coagulation factors and flbrinolysis research methodologies in human diabetes. Part 2 [M]. New York:De Gruyter Berlim, 1995. 125-46.
[4] Smulders RA, Stehouwer CD, Schalk Wijk CG, et al. Distinct associations of HbAlc and the urinary excretion of pentosidine, an advanced glycosylation end-product,with markers of endothelial function in insulin-dependent diabetes mellitus [J]. Thromb Haemost, 1998, 80(1):52-7.
[5] Morise T, Takeuchi Y, Kawano M, et al. Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients[J]. Diabetes Care, 1995, 18(1):87-9.
[6] Stehouwer CD, Fischer HR. Endothelial dysfunction precedes development of microalbuminuria in IDDM [J]. Diabetes, 1995, 44(4):561.
[7] Phenekos C, Siafaka-Kapadai A, Trapali M, et al. Effect ofgliclazide on platelet-activating factor-induced platelet aggregation in patients with non-insulin-dependent diabetes mellitus [J]. Metabolism, 1992,41(5 Suppl):30-2.
[8] Cavallo-Perin P, Lupia E, Gruden G, et al. Increased blood levels of platelet-activating factor in insulin-dependent diabetic patients with microalbuminuria [J]. Nephrol Dial Transplant, 2000, 15(7):994-9.
[9] Kudolo GB, DeFronzo RA. Urinary platelet-activating factor excretion is elevated in non-insulin dependent diabetes mellitus [J].Prostaglandins Other Lipis Mediat, 1999, 57(2-3):87-98.
[10] Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes[J]. Diabetes, 1999, 48(9):1856-62.
[11] Ak G, Buyukberber S, Sevinc A, et al. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2diabetes mellitus [J]. J Diabetes Complications, 2001, 15(3):150-7.

[1]	吕伟明；雷尚通；张强；张赟建；王深明；石汉平；. 精氨酸对糖尿病的作用观察[J]. 南方医科大学学报, 2006, 26(10): 1434-.
[2]	陈世伟；张立实；张红敏；冯晓凡；. 大豆异黄酮对胰岛素抵抗大鼠低度炎症因子水平的影响[J]. 南方医科大学学报, 2006, 26(10): 1484-1486.
[3]	郭津含；唐红；. 脉冲多普勒组织成像技术评价2型糖尿病患者的左室舒张功能[J]. 南方医科大学学报, 2006, 26(10): 1515-1517.
[4]	贾贺堂；张素华；纪立农；韩学尧；. 北京市100个早发糖尿病家系MODY1基因突变的筛查[J]. 南方医科大学学报, 2006, 26(09): 1301-1303.
[5]	钱孝贤；陈燕铭；吴伟康；刘勇；周彬；刘金来；陈璘；. 伊贝沙坦对糖尿病大鼠心脏一氧化氮系统的影响[J]. 南方医科大学学报, 2006, 26(09): 1359-1362.
[6]	张定康；俞守义；耿仁文；秦建增；谭筱江；. 国内应用胰岛素泵治疗2型糖尿病疗效循证研究[J]. 南方医科大学学报, 2006, 26(08): 1211-1212.
[7]	关美萍, 沈洁, 李晨钟, 谢翠华, 薛耀明. 经皮左锁骨下动脉导管药盒系统置入术+药物灌注治疗糖尿病足1例报道[J]. 南方医科大学学报, 2005, 25(11): 1417-1417.
[8]	王玲, 黄新胜, 周颖玲, 陈纪言, 林曙光. 血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂改善2型糖尿病合并动脉粥样硬化患者血管内皮功能近期疗效的对比研究[J]. 南方医科大学学报, 2005, 25(08): 967-971.
[9]	方咏红, 张继平, 周少雄, 郑菊芬, 余永卫, 晏世刚, 范文奎, 陈月崧. 2型糖尿病合并肾病患者血清内皮素含量的临床分析[J]. 南方医科大学学报, 2005, 25(08): 1007-1008,1011.
[10]	王玲, 周颖玲, 林曙光. 高敏C反应蛋白水平的变化与ACEI/D基因多态性的相关性分析[J]. 南方医科大学学报, 2005, 25(06): 691-695.
[11]	陈雪梅, 邵虹, 邱晓敏, 李蜀光, 张耿新, 潘鉴枝. 佛山市老年人体重指数与糖尿病的关系[J]. 南方医科大学学报, 2005, 25(02): 216-217,222.
[12]	关美萍, 李晨钟, 薛耀明, 沈洁, 高方, 罗祥容. 2型糖尿病合并高血压病患者尿微量白蛋白患病率研究[J]. 南方医科大学学报, 2005, 25(02): 234-235.
[13]	李永勤¹, 王胜军¹, 高方², 邓亲恺¹. 糖尿病自主神经病变的皮肤流电响应检测分析[J]. 南方医科大学学报, 2004, 24(10): 1140-1142,1146.
[14]	李晨钟, 薛耀明, 高方, 汪敏. 2型糖尿病患者血清超灵敏C反应蛋白水平的检测[J]. 南方医科大学学报, 2004, 24(07): 791-793.
[15]	陈刚, 林丽香, 庄维特, 姚瑾, 黄惠彬, 梁继兴, 张芳林, 温俊平, 李连涛, 林苗, 林庆明. 卡托普利对糖尿病性心肌病大鼠心肌组织能量代谢和炎症反应的影响[J]. 南方医科大学学报, 2004, 24(07): 827-828,831.